Vertex Pharmaceuticals Incorporated (ETR:VX1)

Market Cap	100.35B -5.5%
Revenue (ttm)	9.99B +10.3%
Net Income	3.13B
EPS	12.12
Shares Out	n/a
PE Ratio	32.04
Forward PE	23.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8
Average Volume	128
Open	396.70
Previous Close	397.55
Day's Range	396.70 - 396.70
52-Week Range	312.65 - 478.10
Beta	0.46
RSI	54.36
Earnings Date	Feb 12, 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: VX1

Financial Performance

Financial numbers in USD